Modeling and Simulation - PK/PD Archives | Page 32 of 42

Publication

Plasma Topiramate Concentrations from Doses Associated with Neuroprotection Against White Matter Injury and Stroke in Two Strains of Rat Pups

Cerebral white matter (WM) injury and stroke are common neuropathological injuries in newborns with congenital…

CertaraMarch 1, 2013

Publication

Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data

This article reports an analysis that aims to quantify the effect of fingolimod, an oral…

CertaraMarch 1, 2013

Publication

Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox

Although smallpox has been eradicated, the United States government considers it a "material threat" and…

CertaraMarch 1, 2013

Knowledge Base

Saturable Drug Absorption

Drug absorption is the process by which a drug molecule moves from the site of…

CertaraFebruary 26, 2013

Blog Knowledge Base

Nonlinear PK: What Does That Mean?

You may come across a phrase like the following and wonder what it means: “……

CertaraFebruary 17, 2013

Knowledge Base

Why Cmax is a Continuous Variable and Tmax is a Categorical Variable

The maximum observed concentration (Cmax) and the time of Cmax (tmax) are both obtained directly…

CertaraFebruary 11, 2013

Knowledge Base

What is Quantification Anyway?

Bioanalytical analysis is a fundamental tool for the pharmacokineticist. The results of a bioanalysis are…

CertaraFebruary 5, 2013

Publication

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction with Physiologically-based Pharmacokinetic Simulations

BMS-690514, a selective inhibitor of the ErbB and vascular endothelial growth factor receptors, has shown…

CertaraFebruary 1, 2013

Publication

Bioavailability of Intranasal vs. Rectal Diazepam

There remains an unmet medical need in the out-of-hospital management of seizure emergencies because older…

CertaraFebruary 1, 2013

Publication

Analysis of Level A In Vitro-In Vivo Correlations for an Extended-release Formulation with Limited Bioavailability

A two-stage, numerical deconvolution approach was employed to develop level A in vitro–in vivo correlations…

CertaraJanuary 21, 2013

Modeling and Simulation – PK/PD

Plasma Topiramate Concentrations from Doses Associated with Neuroprotection Against White Matter Injury and Stroke in Two Strains of Rat Pups

Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data

Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox

Saturable Drug Absorption

Nonlinear PK: What Does That Mean?

Why Cmax is a Continuous Variable and Tmax is a Categorical Variable

What is Quantification Anyway?

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction with Physiologically-based Pharmacokinetic Simulations

Bioavailability of Intranasal vs. Rectal Diazepam

Analysis of Level A In Vitro-In Vivo Correlations for an Extended-release Formulation with Limited Bioavailability

Newsletter sign up

Quick links

Solutions

Contact